Inflamed immune phenotype predicts favorable clinical outcomes of immune checkpoint inhibitor therapy across multiple cancer types.

The subgroup analyses showed similar trends, although the improvement in PFS for IIP versus non-IIP patients did not reach statistical significance within the subgroup of MSS/MSI-L and TMB-low patients (HR 0.43, 95% CI 0.17 to 1.07, p=0.062), or in the subgroup of patients receiving the ICI as first-line treatment (HR 0.74, 95% CI 0.53 to 1.04, p=0.078, online supplemental figure 6B ).

also in 111,027 other papers